Why It Matters

Soter Bio LLC, a Houston-based contract development and manufacturing organization (CDMO) specializing in mRNA, cell therapy, gene therapy, and plasmid DNA production, has terminated its lobbying relationship with Tenagrity Solutions LLC after roughly 18 months of advocacy work.

Tenagrity Solutions LLC filed a termination lobbying disclosure for Soter Bio LLC covering the third quarter of 2026, with the relationship terminated on July 25.

The engagement itself carried minimal financial weight. Tenagrity Solutions LLC reported zero filing amounts for its lobbying work on behalf of Soter Bio LLC. For context, Tenagrity Solutions received $130,000 in lobbying fees from another client, 1Day Sooner Action Project Inc., suggesting the Soter Bio relationship was not a major revenue contributor.

Broader Context

Soter Bio's lobbying agenda centered on positioning itself as a critical player in domestic pharmaceutical manufacturing and biodefense. The company has sought to raise awareness of its capabilities among Congress, the Department of Defense, and the Department of Health and Human Services (HHS). It submitted appropriations requests for HHS funding focused specifically on domestic pharmaceutical manufacturing capacity and framed that capacity as essential for disaster preparedness.

The timing of this engagement reflects broader federal interest in reshoring pharmaceutical and biological manufacturing. The company also pursued a Department of Defense chemical, biological, radiological, and nuclear (CBRN) facility visit, signaling alignment with military biodefense priorities.

The proposed HHS budget for fiscal year 2027 represented a 4 percent cut below the fiscal year 2026 enacted levels, potentially affecting the availability of new appropriations for manufacturing initiatives that Soter Bio was pursuing.

Caroline DeBerry, founder and CEO of Tenagrity Solutions, and a lawyer with prior Hill experience as a legislative assistant in the office of former Rep. John J. Duncan Jr. (R-TN-2), served as the primary lobbyist on the engagement.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article